Literature DB >> 6152055

Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.

R B Smith, P D Kroboth, J T Vanderlugt, J P Phillips, R P Juhl.   

Abstract

Six fasting male subjects (20-32 years of age) received an oral tablet and an IV 1.0-mg dose of alprazolam in a crossover-design study. Alprazolam plasma concentration in multiple samples during 36 h after dosing was determined by electron-capture gas-liquid chromatography. Psychomotor performance tests, digit-symbol substitution (DSS), and perceptual speed (PS) were administered at 0, 1.25, 2.25, 5.0, and 12.5 h. Sedation was assessed by the subjects and by an observer using the Stanford Sleepiness Scale and a Nurse Rating Sedation Scale (NRSS), respectively. Mean kinetic parameters after IV and oral alprazolam were as follows: volume of distribution (Vd) 0.72 and 0.84 l/kg; elimination half-life (t1/2) 11.7 and 11.8 h; clearance (Cl) 0.74 and 0.89 ml/min/kg. There were no significant differences between IV and oral alprazolam in Vd, t1/2, or area under the curve. The mean fraction absorbed after oral administration was 0.92. Performance on PS and DSS tests was impaired at 1.25 and 2.5 h, but had returned to baseline at 5.0 h for both treatments. Onset of sedation was rapid after IV administration and the average time of peak sedation was 0.48 h. Sedation scores were significantly lower during hour 1 after oral administration than after IV, but were not significantly different at later times. Alprazolam is fully available after oral administration and kinetic parameters are not affected by route of administration. With the exception of rapidity of onset, the pharmacodynamic profiles of IV and oral alprazolam are very similar after a 1.0-mg dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6152055     DOI: 10.1007/BF00431449

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.

Authors:  D J Greenblatt; R I Shader; K Franke; D S MacLaughlin; J S Harmatz; M D Allen; A Werner; E Woo
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

2.  Quantification of sleepiness: a new approach.

Authors:  E Hoddes; V Zarcone; H Smythe; R Phillips; W C Dement
Journal:  Psychophysiology       Date:  1973-07       Impact factor: 4.016

3.  Profile of acute tolerance to three sedative anxiolytics.

Authors:  E H Ellinwood; M Linnoila; M E Easler; D W Molter
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

4.  Daytime alertness, insomnia, and benzodiazepines.

Authors:  W Dement; W Seidel; M Carskadon
Journal:  Sleep       Date:  1982       Impact factor: 5.849

5.  Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.

Authors:  R B Smith; P R Gwilt; C E Wright
Journal:  Clin Pharm       Date:  1983 Mar-Apr

6.  Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study.

Authors:  G Chouinard; L Annable; R Fontaine; L Solyom
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety.

Authors:  K C Greiss; R Fogari
Journal:  J Clin Pharmacol       Date:  1980 Nov-Dec       Impact factor: 3.126

8.  Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

Authors:  J P Feighner; G C Aden; L F Fabre; K Rickels; W T Smith
Journal:  JAMA       Date:  1983-06-10       Impact factor: 56.272

9.  Double-blind study of lorazepam and diazepam in status epilepticus.

Authors:  I E Leppik; A T Derivan; R W Homan; J Walker; R E Ramsay; B Patrick
Journal:  JAMA       Date:  1983-03-18       Impact factor: 56.272

10.  Sedative-hypnotics and human performance.

Authors:  L C Johnson; D A Chernik
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  30 in total

1.  The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.

Authors:  J M Scavone; D J Greenblatt; J E Goddard; H Friedman; J S Harmatz; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

3.  Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

Authors:  T A Lasher; J C Fleishaker; R C Steenwyk; E J Antal
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.

Authors:  Tim R M Leufkens; Annemiek Vermeeren; Beitske E Smink; Peter van Ruitenbeek; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

Review 5.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

6.  Lack of effect of influenza vaccine on the pharmacokinetics of antipyrine, alprazolam, paracetamol (acetaminophen) and lorazepam.

Authors:  J M Scavone; G T Blyden; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

Review 7.  Influence of drug formulation on drug concentration-effect relationships.

Authors:  G Castañeda-Hernández; G Caillé; P du Souich
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 8.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

9.  Lack of interaction between disulfiram and alprazolam in alcoholic patients.

Authors:  B Diquet; L Gujadhur; D Lamiable; D Warot; H Hayoun; H Choisy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.